Rxsight Stock Alpha and Beta Analysis
| RXST Stock | USD 50.38 0.81 1.63% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Rxsight. It also helps investors analyze the systematic and unsystematic risks associated with investing in Rxsight over a specified time horizon. Remember, high Rxsight's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Rxsight's market risk premium analysis include:
Beta 1.68 | Alpha 0.0753 | Risk 3.22 | Sharpe Ratio 0.0731 | Expected Return 0.24 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Rxsight |
Rxsight Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Rxsight market risk premium is the additional return an investor will receive from holding Rxsight long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Rxsight. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Rxsight's performance over market.| α | 0.08 | β | 1.68 |
Rxsight expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Rxsight's Buy-and-hold return. Our buy-and-hold chart shows how Rxsight performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Rxsight Market Price Analysis
Market price analysis indicators help investors to evaluate how Rxsight stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Rxsight shares will generate the highest return on investment. By understating and applying Rxsight stock market price indicators, traders can identify Rxsight position entry and exit signals to maximize returns.
Rxsight Return and Market Media
The median price of Rxsight for the period between Sun, Jul 28, 2024 and Sat, Oct 26, 2024 is 50.52 with a coefficient of variation of 7.15. The daily time series for the period is distributed with a sample standard deviation of 3.63, arithmetic mean of 50.69, and mean deviation of 2.88. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 10000 shares by Eric Weinberg of Rxsight at 48.0006 subject to Rule 16b-3 | 08/01/2024 |
2 | Disposition of 2300 shares by Kurtz Ronald M Md of Rxsight at 4.3386 subject to Rule 16b-3 | 08/09/2024 |
3 | RxSight Stock Sees Relative Strength Rating Rise To 91 - Investors Business Daily | 08/19/2024 |
4 | Disposition of 3100 shares by Ilya Goldshleger of Rxsight at 56.111 subject to Rule 16b-3 | 09/17/2024 |
5 | RxSight executive sells over 328k in company stock | 09/23/2024 |
6 | Disposition of 3105 shares by Ilya Goldshleger of Rxsight at 49.2926 subject to Rule 16b-3 | 09/26/2024 |
7 | Disposition of 278 shares by Shelley Thunen of Rxsight at 49.45 subject to Rule 16b-3 | 10/01/2024 |
8 | RxSight executive Shelley Thunen sells shares worth over 726k | 10/02/2024 |
9 | Disposition of 206 shares by Ilya Goldshleger of Rxsight at 48.65 subject to Rule 16b-3 | 10/04/2024 |
10 | Disposition of 3100 shares by Ilya Goldshleger of Rxsight at 48.262 subject to Rule 16b-3 | 10/08/2024 |
11 | Disposition of 3105 shares by Ilya Goldshleger of Rxsight at 48.8231 subject to Rule 16b-3 | 10/10/2024 |
12 | Disposition of 3100 shares by Ilya Goldshleger of Rxsight at 50.1915 subject to Rule 16b-3 | 10/11/2024 |
13 | Disposition of 3100 shares by Ilya Goldshleger of Rxsight at 50.0865 subject to Rule 16b-3 | 10/14/2024 |
14 | RxSight, Inc. A Visionary Small-Cap Stock Pick by Hedge Funds | 10/15/2024 |
15 | Disposition of 3100 shares by Ilya Goldshleger of Rxsight at 49.7799 subject to Rule 16b-3 | 10/16/2024 |
16 | Disposition of tradable shares by Ilya Goldshleger of Rxsight at 50.59 subject to Rule 16b-3 | 10/18/2024 |
17 | Disposition of 3100 shares by Ilya Goldshleger of Rxsight at 49.6778 subject to Rule 16b-3 | 10/22/2024 |
18 | RxSight Inc Shares Gap Down to 48.73 on Oct 23 | 10/23/2024 |
19 | RxSight, Inc. Insider Ilya Goldshleger Sells 3,100 Shares | 10/25/2024 |
About Rxsight Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Rxsight or other stocks. Alpha measures the amount that position in Rxsight has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 10.7 | 10.67 | 9.14 | 7.01 | Days Of Inventory On Hand | 162.19 | 195.64 | 180.07 | 312.42 |
Rxsight Upcoming Company Events
As portrayed in its financial statements, the presentation of Rxsight's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Rxsight's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Rxsight's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Rxsight. Please utilize our Beneish M Score to check the likelihood of Rxsight's management manipulating its earnings.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Rxsight
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Rxsight Stock Analysis
When running Rxsight's price analysis, check to measure Rxsight's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rxsight is operating at the current time. Most of Rxsight's value examination focuses on studying past and present price action to predict the probability of Rxsight's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rxsight's price. Additionally, you may evaluate how the addition of Rxsight to your portfolios can decrease your overall portfolio volatility.